Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
2002 1
2003 1
2004 3
2006 1
2007 10
2008 18
2009 17
2010 22
2011 23
2012 28
2013 33
2014 33
2015 39
2016 35
2017 45
2018 43
2019 35
2020 50
2021 58
2022 37
2023 43
2024 45
2025 44
2026 25

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

588 results

Results by year

Filters applied: . Clear all
Page 1
Long-term follow-up of oral decitabine/cedazuridine plus venetoclax for older or unfit patients with newly diagnosed acute myeloid leukemia.
Htut TW, Kekedjian J, Short N, Bazinet A, Alvarado Y, Bataller A, Issa G, Borthakur G, Maiti A, Yilmaz M, Jain N, Masarova L, Chien K, Senapati J, Jabbour E, Montalban-Bravo G, Pierce S, DiNardo CD, Kadia T, Daver N, Konopleva M, Huang X, Kantarjian H, Garcia-Manero G, Ravandi F. Htut TW, et al. Among authors: borthakur g. Haematologica. 2026 Jul 2. doi: 10.3324/haematol.2026.301126. Online ahead of print. Haematologica. 2026. PMID: 42389833 Free article.
Investigational clinical trial agents versus conventional second salvage therapies in patients with relapsed/refractory acute myeloid leukemia.
Nguyen D, Kantarjian HM, Bidikian A, Manuel CM, Qiao W, Ning J, DiNardo CD, Kadia TM, Daver N, Borthakur G, Jabbour E, Yilmaz M, Maiti A, Sasaki K, Montalban-Bravo G, Chien K, Hammond D, Pierce S, Andreeff M, Ravandi F, Short NJ, Garcia-Manero G, Issa GC. Nguyen D, et al. Among authors: borthakur g. Clin Cancer Res. 2026 Jun 22. doi: 10.1158/1078-0432.CCR-26-0951. Online ahead of print. Clin Cancer Res. 2026. PMID: 42329225
Final analysis of phase 2 clinical trial of ruxolitinib and azacitidine combination therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasms.
Arora S, Senapati J, Deshmukh I, Bose P, Masarova L, Loghavi S, Wang X, Nogueras-Gonzalez G, Montalban-Bravo G, Borthakur G, DiNardo CD, Kadia T, Zhou L, Saenz D, Halim H, Alvarado Y, Ohanian M, Takahashi K, Short NJ, Jabbour E, Ravandi F, Garcia-Manero G, Pemmaraju N, Daver NG. Arora S, et al. Among authors: borthakur g. J Hematol Oncol. 2026 Jun 16. doi: 10.1186/s13045-026-01813-7. Online ahead of print. J Hematol Oncol. 2026. PMID: 42304430 Free article.
Long-Term Outcomes of Azacitidine, Venetoclax and Gilteritinib in Newly Diagnosed FLT3-Mutated AML.
Short NJ, Kantarjian HM, Daver NG, Azevedo RS, Karrar O, DiNardo CD, Kadia TM, Yilmaz M, Maroun MM, Hachem MCR, Borthakur G, Issa GC, Shpall EJ, Popat UR, Huang X, Qiao W, Nasr LF, Macaron W, Abramova R, Garcia-Manero G, Konopleva M, Ravandi F. Short NJ, et al. Among authors: borthakur g. Blood Adv. 2026 May 27:bloodadvances.2026019841. doi: 10.1182/bloodadvances.2026019841. Online ahead of print. Blood Adv. 2026. PMID: 42200455
Prognostic impact of ASXL1 mutations in acute myeloid leukemia treated with lower intensity therapy.
Marvin-Peek J, DiNardo CD, Loghavi S, Ravandi F, Borthakur G, Daver NG, Kadia TM, Jabbour E, Dunbar A, Tang G, Short NJ, Haddad FG, Abbas HA, Kugler E, Maiti A, Issa GC, Takahashi K, Bhalla K, Pemmaraju N, Alvarado Y, Shpall EJ, Popat U, Ramdial J, Champlin RE, Kantarjian HM, Garcia-Manero G, Senapati J. Marvin-Peek J, et al. Among authors: borthakur g. Cancer. 2026 May 15;132(10):e70434. doi: 10.1002/cncr.70434. Cancer. 2026. PMID: 42089434 Free PMC article.
Cladribine With Low-Dose Cytarabine and Venetoclax Alternating With Azacitidine and Venetoclax for Newly Diagnosed Acute Myeloid Leukemia.
Kadia TM, Bataller A, Bazinet A, Borthakur G, Daver N, Short NJ, DiNardo C, Jabbour E, Rausch CR, Issa GC, Pemmaraju N, Ohanian M, Maiti A, Montalban-Bravo G, Sasaki K, Bouligny IM, Yilmaz M, Haddad FG, Masarova L, Chien K, Alvarado Y, Jain N, Popat U, Shpall E, Loghavi S, Qiao W, Wang X, Garcia-Manero G, Ravandi F, Kantarjian HM. Kadia TM, et al. Among authors: borthakur g. Am J Hematol. 2026 Jul;101(7):1737-1747. doi: 10.1002/ajh.70328. Epub 2026 Apr 25. Am J Hematol. 2026. PMID: 42035228 Clinical Trial.
Blinatumomab and Ponatinib Versus Hyper-CVAD and Ponatinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Propensity Score Analysis.
Sasaki K, Kantarjian H, Rausch CR, Goulart H, Jain N, Huang X, Hachem M, Wierda WG, Kadia TM, Borthakur G, Issa GC, Alvarado Y, Pemmaraju N, Garris R, Ravandi F, Garcia-Manero G, Short NJ, Jabbour E. Sasaki K, et al. Among authors: borthakur g. Am J Hematol. 2026 Jul;101(7):1717-1722. doi: 10.1002/ajh.70325. Epub 2026 Apr 24. Am J Hematol. 2026. PMID: 42031676 No abstract available.
Integrated Analysis of Genomics, Molecular Responses, and Outcomes of CBF-AML with FLAG-Based Therapy on a Phase II Trial.
Senapati J, Kantarjian HM, Ayoub E, Quesada AE, Loghavi S, Sasaki K, Kadia TM, Daver N, DiNardo CD, Jain A, McCabe M, Haddad FG, Brandt M, Tang G, Alvarado Y, Farish K, Abbas HA, Garcia-Manero G, Ravandi F, Andreeff M, Borthakur G. Senapati J, et al. Among authors: borthakur g. Blood Cancer Discov. 2026 Jul 1;7(4):572-585. doi: 10.1158/2643-3230.BCD-25-0477. Blood Cancer Discov. 2026. PMID: 41979452 Free PMC article. Clinical Trial.
A phase I open label study of fostamatinib, a SYK inhibitor, in patients with lower-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Croden J, Garcia-Manero G, Chien K, DiNardo C, Borthakur G, Hammond D, Bose P, Short N, Romero L, Shneider H, Hatfield M, Pierce S, Huang X, Hwang H, Montalban-Bravo G. Croden J, et al. Among authors: borthakur g. Leuk Lymphoma. 2026 Jun;67(7):1580-1586. doi: 10.1080/10428194.2026.2650674. Epub 2026 Mar 30. Leuk Lymphoma. 2026. PMID: 41909958 Clinical Trial.
588 results